EU Targets Generics, Inspection Shortfalls & Environmental Assessments
Executive Summary
As the European Commission prepares to publish its proposals for overhauling the EU pharmaceutical legislation at the end of the year, member states have been discussing a range of technical and legal issues such as the scope of the centralized approval procedure, the use of electronic product information and the shortage of inspection capacities.
You may also be interested in...
EU Prepares To Pilot Electronic Product Information
The adoption of a new common standard opens the way to the implementation of EU-wide electronic formats for documents such as the summary of product characteristics and the patient information leaflet.
Austria & Germany Call For ‘Competitiveness Check’ On EU Pharma Revision Package
The two countries want the European Commission’s proposals to be more closely examined for their possible negative effect on pharmaceutical investment decisions. The industry federation EFPIA says it is surprised more EU member states aren’t taking the same stance.
EU Bodies Agree On Ways To Future-Proof EMA Funding System
EU ministers say that implementing an appropriate fee structure that is more in line with actual costs will promote innovation in the pharmaceutical sector while ensuring “fair access” to safe and effective medicines for patients.